Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.155
+0.025 (0.80%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Voyager Therapeutics Revenue
In the year 2024, Voyager Therapeutics had annual revenue of $80.00M, down -68.00%. Voyager Therapeutics had revenue of $6.28M in the quarter ending December 31, 2024, a decrease of -93.03%.
Revenue (ttm)
$80.00M
Revenue Growth
-68.00%
P/S Ratio
2.28
Revenue / Employee
$465,122
Employees
172
Market Cap
174.45M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 80.00M | -170.01M | -68.00% |
Dec 31, 2023 | 250.01M | 209.10M | 511.16% |
Dec 31, 2022 | 40.91M | 3.49M | 9.33% |
Dec 31, 2021 | 37.42M | -133.71M | -78.14% |
Dec 31, 2020 | 171.13M | 66.74M | 63.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VYGR News
- 18 days ago - Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - GlobeNewsWire
- 5 weeks ago - Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewsWire
- 6 weeks ago - Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast - GlobeNewsWire
- 6 weeks ago - Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease - GlobeNewsWire
- 6 weeks ago - The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire
- 7 weeks ago - Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire